Orgenesis Inc. Long-Term Investments

Long-Term Investments of ORGS for past 10 years: annual, quarterly and twelve month trailing (TTM) including Long-Term Investments growth rates and interactive chart. An accounting item that represents the company's investments, including stocks, bonds, real estate, and cash. Long-term investments are assets that a company intends to hold for more than a year. The long-term investment account differs largely from the short-term investment account in that short-term investments will most likely be sold, whereas the long-term investments will not be sold for years and, in some cases, may never be sold.


Highlights and Quick Summary

  • Long-Term Investments for the quarter ending September 29, 2021 was $397 Thousand (a 148.13% increase compared to previous quarter)
  • Year-over-year quarterly Long-Term Investments increased by 126.86%
  • Annual Long-Term Investments for 2020 was $175 Thousand (a -41.47% decrease from previous year)
  • Annual Long-Term Investments for 2019 was $299 Thousand (a 109.09% increase from previous year)
  • Annual Long-Term Investments for 2018 was $143 Thousand (a 68.24% increase from previous year)
Visit stockrow.com/ORGS for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Long-Term Investments of Orgenesis Inc.

Most recent Long-Term Investmentsof ORGS including historical data for past 10 years.

Interactive Chart of Long-Term Investments of Orgenesis Inc.

Orgenesis Inc. Long-Term Investments for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 $0.4 $0.16 $0.16
2020 $0.18 $0.28 $0.27 $0.26 $0.18
2019 $0.3 $0.62 $0.62 $0.57 $0.3
2018 $0.14 $0.09 $0.09 $1.71 $0.14
2017 $1.32 $0.48 $0.25 $1.66

Business Profile of Orgenesis Inc.

Sector: Healthcare
Industry: Biotechnology
Orgenesis Inc., a biotech company, focusing on cell and gene therapies (CGTs). The company develops a Point of Care (POCare) platform includes three enabling components: a pipeline of licensed POCare Therapeutics that are processed and produced in closed, automated POCare Technology systems across a collaborative POCare Network. It focuses on autologous therapies, with processes and systems that are developed for each therapy using a closed and automated processing system approach that is validated for compliant production near the patient at their point of care for treatment of the patient. The company's POCare Network brings together patients, doctors, industry partners, research institutes, and hospitals for the clinical development and production of therapies worldwide. Orgenesis Inc. has a collaboration agreement with Savicell Diagnostics Ltd. The company was formerly known as Business Outsourcing Service, Inc. and changed its name to Orgenesis Inc. in August 2011. Orgenesis Inc. was incorporated in 2008 and is based in Germantown, Maryland.